This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
However, in chemical nomenclature, the prefix "oxy" is associated with ether functional groups, i.e., a compound with an oxygen atom connected to two alkyl or aryl groups (R-O-R), therefore, using "oxy" within the name of a steroid class may be misleading. One can find clear examples of "oxygenated" to refer to a broad class of organic molecules containing a variety of oxygen containing functional groups in other domains of organic chemistry, and it is appropriate to use this convention. Even though "keto" is a standard prefix in organic chemistry, the 1989 recommendations of the Joint Commission on Biochemical Nomenclature discourage the application of the prefix "keto" for steroid names, and favor the prefix "oxo" (e.g., 11-oxo steroids rather than 11-keto steroids), because "keto" includes the carbon that is part of the steroid nucleus and the same carbon atom should not be specified twice.
=== Randomness of mutations === There is a widespread assumption that mutations are (entirely) "random" with respect to their consequences (in terms of probability). This was shown to be wrong as mutation frequency can vary across regions of the genome, with such DNA repair- and mutation-biases being associated with various factors. For instance, Monroe and colleagues demonstrated that—in the studied plant (Arabidopsis thaliana)—more important genes mutate less frequently than less important ones. They demonstrated that mutation is "non-random in a way that benefits the plant". Additionally, previous experiments typically used to demonstrate mutations being random with respect to fitness (such as the Fluctuation Test and Replica plating) have been shown to only support the weaker claim that those mutations are random with respect to external selective constraints, not fitness as a whole.
=== FA2; 1967 === The new Familia appeared in November 1967 with the same pushrod 987 cc engine as used in the previous generation saloons. It was sold as the "Mazda 1000" in some markets. In July 1968 the rotary-engined version (R100) was introduced, along with a new coupé bodywork which was also available with the 1200 cc piston engine. After an April 1970 facelift (called the "Familia Presto" in the domestic Japanese market), the slightly different OHC "PC" 1-litre engine was also offered. A larger 1169 cc straight-four engined version came along in February 1968, becoming the "Mazda 1200" for export. In this form, the car was first exhibited in Europe at the 1968 Paris Motor Show in the autumn of that year. Power outputs (SAE gross) in Japan of the facelifted, overhead-cam-engined versions were 62 and 75 PS (46 and 55 kW) respectively. The Van (wagon) model was available with either three or five doors, although most export markets only received the five-door version.
==== MeSH D12.125.095 – amino acids, diamino ==== MeSH D12.125.095.104 – arginine MeSH D12.125.095.104.075 – argininosuccinic acid MeSH D12.125.095.104.095 – benzoylarginine-2-naphthylamide MeSH D12.125.095.104.100 – benzoylarginine nitroanilide MeSH D12.125.095.104.400 – homoarginine MeSH D12.125.095.104.525 – ng-nitroarginine methyl ester MeSH D12.125.095.104.587 – nitroarginine MeSH D12.125.095.104.650 – omega-n-methylarginine MeSH D12.125.095.104.900 – tosylarginine methyl ester MeSH D12.125.095.165 – asparagine MeSH D12.125.095.226 – citrulline MeSH D12.125.095.307 – cystathionine MeSH D12.125.095.369 – cystine MeSH D12.125.095.390 – diaminopimelic acid MeSH D12.125.095.461 – glutamine MeSH D12.125.095.461.700 – proglumide MeSH D12.125.095.533 – homocystine MeSH D12.125.095.647 – lysine MeSH D12.125.095.647.478 – hydroxylysine MeSH D12.125.095.647.575 – lysinoalanine MeSH D12.125.095.647.750 – polylysine MeSH D12.125.095.765 – ornithine MeSH D12.125.095.765.340 – eflornithine
Sources: en.wikipedia.org
The family then mentioned how Lashay had been tested for Rumination's via a M spike testing, which is testing the pressure at the lower esophageal sphincter, with results that are strongly suggestive of Rumination's. With this information, the family had a very strong denial in the fact that Lashay might have a chronic illness with no treatment instead of just a simple parasitic infection.
The second main legislative body is the Council of the European Union, which is composed of different ministers of the member states. The heads of government of member states also convene a "European Council" (a distinct body) that the TEU article 15 defines as providing the 'necessary impetus for its development and shall define the general political directions and priorities'. It meets each six months and its President (currently former Belgian Prime Minister Charles Michel) is meant to 'drive forward its work', but it does not itself exercise 'legislative functions'. The Council does this: in effect this is the governments of the member states, but there will be a different minister at each meeting, depending on the topic discussed (e.g. for environmental issues, the member states' environment ministers attend and vote; for foreign affairs, the foreign ministers, etc.). The minister must have the authority to represent and bind the member states in decisions. When voting takes place it is weighted inversely to member state size, so smaller member states are not dominated by larger member states. In total there are 352 votes, but for most acts there must be a qualified majority vote, if not consensus. TEU article 16(4) and TFEU article 238(3) define this to mean at least 55 per cent of the Council members (not votes) representing 65 per cent of the population of the EU: currently this means around 74 per cent, or 260 of the 352 votes. This is critical during the legislative process.
In response to Estadão, the Ministry of Communications released a statement with its position regarding the trip. The statement affirms that the minister had official commitments during the trip to the state of São Paulo:The minister fulfilled an official agenda on 26 and 27 January, participating in meetings with the operator Claro, where the company's investment plan in the country was presented; [he also participated in] a technical meeting with the team of the regional office of the affiliated Telebrás; a meeting with the regional manager of the affiliated agency Anatel; and [participated in] a visit and meeting with the BYD group in SP.In an exclusive interview with journalist Reinaldo Azevedo on BandNews FM, Lula declared:I tried this week to talk with Juscelino; minister Juscelino is traveling, he is abroad on ministry business discussing at the telecommunications meeting. I have already asked minister Rui Costa to summon him for Monday so that we can have a conversation because he has the right to prove his innocence, but if he cannot prove his innocence he cannot remain in the government. I guarantee everyone the presumption of innocence.Pressured by allies and opponents regarding the permanence or dismissal of the minister, the president met with Juscelino on 6 March to demand explanations from him regarding the accusations. After the meeting, Lula decided to keep the minister. On his official Twitter profile, Juscelino published:I have just left the Palácio do Planalto, where I had a very positive meeting with president Lula.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.